Catalent Stock News

Catalent, Inc. (NYSE:CTLT) Director Gregory T. Lucier sold 5,068 shares of the businesss stock in a transaction that occurred on Tuesday, November 23rd. The stock was sold at an average price of $127.35, for a total value of $645,409.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is []

In life sciences, research and development BPO services include biometric, competitive intelligence pipeline research, R&D portfolio management, and more. Furthermore, drug development services include clinical data management, regulatory services, and pharmacovigiliance. The global life sciences BPO market is projected to

DUBLIN--(BUSINESS WIRE)--The "Global Nasal Spray Market 2021-2028" report has been added to ResearchAndMarkets.com''s offering. This report denotes that the global nasal spray market is forecasted to register growth at a CAGR of 8.47% from 2021 to 2028. Companies Mentioned Akorn Allergan Apotex Inc Bharat Biotech Catalent Inc Cipla Limited GlaxoSmithKline Johnson and Johnson Novartis International AG Pfizer Inc Proctor and Gamble Co Sanotize Research and Development Sun Pharmaceuticals Industrie

Related Stocks: FREL , TEAM , CRWD , DE , SE , IWD , CTLT , SYK , BILL , OKE , APD , ABBV , SCHH , GSHD , FIVN , CBRE , STL , EMR ,

Equities analysts expect Catalent, Inc. (NYSE:CTLT) to post $1.16 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Catalents earnings, with the lowest sales estimate coming in at $1.14 billion and the highest estimate coming in at $1.20 billion. Catalent reported sales of $910.80 million during []

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will virtually present at the Stephens Annual Investment Conference at 11:00 a.m. ET on November 29, 2021. A live webcast of the presentation will be accessible at http://investor.catalent.com and w

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient

The Formulation Development Outsourcing Market research report is a point-by-point investigation of the Formulation Development Outsourcing industry that represents considerable authority in recognizing the development capability of the global Formulation Development Outsourcing Market and potential opportunities in the market. Secondary

B. Metzler seel. Sohn & Co. Holding AG boosted its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 84.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,749 shares of the companys stock after purchasing an additional 2,177 shares during the quarter. B. Metzler []

Catalent, Inc. (NYSE:CTLT) was the recipient of some unusual options trading on Wednesday. Stock investors acquired 5,049 call options on the company. This represents an increase of approximately 1,672% compared to the typical daily volume of 285 call options. Shares of Catalent stock opened at $130.05 on Thursday. The company has a quick ratio of []

The Vegetarian Softgel Capsules market is a comprehensive market research report which provides market analysis with a historical & futuristic perspective for the following parameters; market size, revenue, demand, and supply data (as applicable). The report offers a detailed market

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Catalent, Inc. (CTLT) CEO John Chiminski on Q3 2021 Results - Earnings Call Transcript

Catalent's (CTLT) robust performance across most of its segments drives its first-quarter fiscal 2022 top line.

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene th